Daiichi Sankyo promotes Marielle Cohard-Radice to new global head of development

6 September 2016

Japanese drug major Daiichi Sankyo (TYO: 4568) today announced the appointment of Marielle Cohard-Radice, as executive vice president, global head of development, effective September 2, 2016.

In her new role, Dr Cohard-Radice will report to Glenn Gormley, senior executive officer and global head, R&D, at Daiichi Sankyo and chairman of the board and president, Daiichi Sankyo Inc, and will have responsibility for the development strategy and portfolio planning for the Cardiovascular-Metabolism and Internal Medicine therapeutic areas. Global Oncology R&D will continue to be led by Antoine Yver, who was appointed executive vice president earlier this year. Marielle's team will be responsible for supporting the oncology clinical development group.

"Dr Cohard-Radice brings more than 25 years of experience and success in the global development of medicines," said Dr Gormley, adding: "Marielle is a proven leader who simultaneously drives accountability and collaboration across global teams, always with a keen focus on the needs of patients."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK